Eli Lilly & Co., US5324571083

Lam Research Corporation stock (US5324571083): Q4 sales beat on stronger wafer equipment demand

02.06.2026 - 08:51:03 | ad-hoc-news.de

Lam Research reported Q4 CY2025 revenue of $5.34 billion on 06/02/2026, ahead of analyst estimates, while Wall Street's latest consensus price target also points higher. The Nasdaq-listed chip equipment maker remains tied to memory and foundry spending in the United States.

Eli Lilly & Co., US5324571083
Eli Lilly & Co., US5324571083

Lam Research Corporation drew fresh attention on 06/02/2026 after StockStory reported that Q4 CY2025 revenue rose 22.1% year over year to $5.34 billion, above the $5.25 billion analyst estimate, while next-quarter revenue guidance of $5.7 billion at the midpoint came in 6.2% above expectations. The stock was last quoted at $210.41 on the Nasdaq, and the same report said analysts had a consensus one-year price target of $274.90 as of 06/02/2026.

The move matters in the United States because Lam Research is a Nasdaq-listed semiconductor equipment supplier with direct exposure to domestic chip-capex cycles, especially memory and foundry spending. Investors tracking the stock from Germany can also watch the same name on international market data services, although the primary listing remains on Nasdaq under LRCX.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

  • Name: Lam Research
  • Sector/industry: Semiconductor equipment
  • Headquarters/country: Fremont, United States
  • Core markets: United States, Asia, and global semiconductor manufacturing hubs
  • Key revenue drivers: Wafer fabrication equipment, services, and refurbishment for integrated-circuit production
  • Home exchange/listing venue: Nasdaq (LRCX)
  • Trading currency: USD

Lam Research Corporation: core business model

Lam Research sells wafer fabrication equipment and related services used in the manufacture of integrated circuits, with demand linked to customer spending on memory, logic, and foundry production tools.

Latest quarterly results for Lam Research Corporation at a glance

For Q4 CY2025, reported on 06/02/2026, revenue reached $5.34 billion versus the $5.25 billion consensus, and the company said next-quarter revenue should reach $5.7 billion at the midpoint, above the Street view cited in the same report. That combination of an earnings beat and a firmer guide is the main near-term catalyst in today's tape, even as the stock remains dependent on a capital-spending rebound across chipmakers.

StockStory also said Lam Research's EPS has compounded at 17.3% annually over the last five years, faster than revenue growth of 10.3%, which helps explain why the market continues to focus on operating leverage when wafer-equipment demand improves.

Read more

Additional news and developments on the stock can be explored via the linked overview pages.

More news on this stockInvestor relations

Sentiment and reactions on Lam Research Corporation

Q4 results and the updated outlook are the main topics investors are likely to discuss after the latest Nasdaq-linked update.

YouTubeXTikTokInstagram

Conclusion

The latest quarter gives Lam Research a clearer short-term narrative on Nasdaq, with revenue ahead of estimates and guidance above expectations in the 06/02/2026 update. In that context, the valuation lens also matters, because the reported consensus target of $274.90 suggests the market is still weighing a better spending cycle against the volatility of semiconductor equipment demand.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.

So schätzen die Börsenprofis Eli Lilly & Co. Aktien ein!

<b>So schätzen die Börsenprofis  Eli Lilly &amp; Co. Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
en | US5324571083 | ELI LILLY & CO. | boerse | 69469146 | bgmi